1-6 of 6
Authors: Michael L Rich
Journal Article
Safety and Effectiveness of 3 Novel All-Oral Shortened Regimens for Rifampicin- or Multidrug-Resistant Tuberculosis in Kazakhstan Open Access
Clinical Infectious Diseases, Volume 79, Issue 4, 15 October 2024, Pages 1046–1053, https://doi.org/10.1093/cid/ciae305
Published: 04 June 2024
Journal Article
Pregnancy and Birth Outcomes in Patients With Multidrug-Resistant Tuberculosis Treated With Regimens That Include New and Repurposed Drugs Open Access
Clinical Infectious Diseases, Volume 78, Issue 1, 15 January 2024, Pages 144–148, https://doi.org/10.1093/cid/ciad445
Published: 22 August 2023
Journal Article
Safety and Effectiveness Outcomes From a 14-Country Cohort of Patients With Multi-Drug Resistant Tuberculosis Treated Concomitantly With Bedaquiline, Delamanid, and Other Second-Line Drugs Open Access
Clinical Infectious Diseases, Volume 75, Issue 8, 15 October 2022, Pages 1307–1314, https://doi.org/10.1093/cid/ciac176
Published: 04 March 2022
Journal Article
Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort Open Access
Clinical Infectious Diseases, Volume 75, Issue 6, 15 September 2022, Pages 1006–1013, https://doi.org/10.1093/cid/ciac019
Published: 13 January 2022
Journal Article
Improving Outcomes for Multidrug-Resistant Tuberculosis: Aggressive Regimens Prevent Treatment Failure and Death Get access
Clinical Infectious Diseases, Volume 59, Issue 1, 1 July 2014, Pages 9–15, https://doi.org/10.1093/cid/ciu209
Published: 11 April 2014
Journal Article
Improved Retention Associated With Community-Based Accompaniment for Antiretroviral Therapy Delivery in Rural Rwanda Get access
Clinical Infectious Diseases, Volume 56, Issue 9, 1 May 2013, Pages 1319–1326, https://doi.org/10.1093/cid/cis1193
Published: 18 December 2012
